



FACTSHEET Specialty pharma meets M&A competence

As a globally operating company headquartered in Germany, CHEPLAPHARM has created a leading and sustainable platform for specialty pharma during the past two decades. We invest worldwide in well-established pharmaceutical brands which have been developed and introduced by research-based pharmaceutical companies. In the last 12 months (as of 09/30/2021), CHEPLAPHARM achieved annual sales of more than 940 million euros1.

¹ Including Net sales and sales/profit generated during the transitional phase of acquired products

Track Record

During the past 20 years, the owner family Braun together with its team successfully concluded more than 125 product acquisitions with well-known pharmaceutical companies in more than 145 countries. The total deal value exceeds more than 3,3 billion euros. Our achievements are a solid foundation for our future development.

International Footprint

We are a globally active company and value the trustful cooperation with our long- established partners, their local network to stakeholders as well as their market knowledge. CHEPLAPHARM operates in more than 145 countries, holding more than 2,500 registrations worldwide.

Our subsidiaries, located in strategically selected markets such as France for example, reinforce our International Footprint.

Sales by Geographical Position

CHEPLAPHARM, with headquarters in Northern Germany, is characterized by its noticeable European presence: The main turnover is generated in Europe, followed by countries in Asia and the Americas. The remaining turnover is divided equally among the Rest of the World.

Our Portfolio

With a clearly defined focus on selected pharmaceutical brands and niche products we offer a diversified portfolio covering a range of therapeutic areas and indications.

Primary therapeutic areas:

- Cardiology
- Gastroenterology
- Gynaecology
- Haematology
- Immunology
- Infectiology
- Metabolic disorders
- Neuropsychiatry
- Oncology
- Ophthalmology

CHEPLAPHARM at a Glance

- As a sustainable platform for specialty pharma, we invest globally in the long-established branded products of research-based pharmaceutical companies and enhance them carefully and with a lot of experience. Our basis is our many years of experience in M&As and transfers.
- We market branded niche products globally in more than 145 countries.
- We generate annually increasing growth rates.

